Tribulus & Gokshura Men's Blend Capsules

The first thing to say about this product is the thing most datasheets leave out: gokshura and tribulus are not two plants. Both names point at Tribulus terrestris L., family Zygophyllaceae. Gokshura is the Ayurvedic Pharmacopoeia of India name for the dried ripe fruit, and it is the fruit that Indian collection and cultivation in Rajasthan, Gujarat and Madhya Pradesh supplies; tribulus, as the sports-nutrition trade uses the word, generally means the aerial parts of Bulgarian or Mediterranean material selected for protodioscin. A capsule that lists both is therefore a two-plant-part blend of one species, and Thovek builds it that way on purpose rather than pretending to a botanical variety that does not exist. The gokshura fraction is a fruit extract standardised on total saponins; the tribulus fraction is an aerial-part extract from a chemotype that genuinely supports a protodioscin figure. The house reference build is a size 0 shell at a 500 mg fill, 350 mg of fruit extract at 40% total saponins with 150 mg of aerial-part extract carrying a declared protodioscin content, rebuilt to a buyer's brief on ratio, strength and count. The chemistry behind that split is where money is won and lost. Protodioscin is a furostanol saponin, CAS 55056-80-9, C51H84O22, molecular weight 1049.20, with the sapogenin diosgenin, CAS 512-04-9, C27H42O3, molecular weight 414.62, quoted as a secondary marker. Protodioscin content is chemotype- and plant-part-dependent and is not a grade that can simply be ordered: work published in Phytochemistry by Dinchev and co-workers in 2008, comparing material from different regions, found Indian and Vietnamese samples effectively free of protodioscin and lacking prototribestin and tribestin altogether, while market surveys of finished tribulus products have reported protodioscin anywhere from 0.17% to 6.49%. Two consequences follow. A 40% total-saponin extract is not a 40% protodioscin extract, and anyone offering the second at the price of the first is either mis-assaying or spiking. And gravimetry cannot substitute for HPLC here, because a gravimetric result weighs a butanol-soluble fraction and cannot resolve saponin class, whereas HPLC names the molecule. We therefore report total saponins gravimetrically on the fruit fraction, quote protodioscin by HPLC only against material whose chemotype supports it, and release both figures on the finished capsule rather than on the input extract. The fill is plant material throughout, so the commercially decisive origin question is again the shell. With the standard hypromellose capsule the product is vegan; with a gelatin shell it is vegetarian at best and carries bovine or porcine origin, which we state on the specification rather than leaving to the packing list. No milk, egg, soy, fish, crustacean, mollusc, peanut, tree nut, sesame, mustard, celery or lupin material and no gluten-bearing cereal enters the process, the material is non-GMO, and magnesium stearate where used is palm-derived rather than tallow-derived. Shells are supplied titanium dioxide free, E171 having lost its EU food-additive authorisation on 7 August 2022. Because this product sells into the men's and sports channels we screen every lot by LC-MS/MS for undeclared synthetic PDE-5 inhibitors — sildenafil, tadalafil and their analogues are the documented adulterants of the category — and we supply the documentation package that third-party banned-substance testing programmes require, without implying certification we do not hold. One logistics note that concerns raw herb rather than capsules: Tribulus terrestris is a declared noxious weed, puncturevine, in parts of the United States and Australia, so viable seed and unprocessed herb can be held at those borders while extract and finished capsules are unaffected. Thovek makes no therapeutic or disease claim for this product; claim wording and substantiation are the buyer's responsibility, botanical health claims remain on hold in the EU under Regulation 1924/2006, and US structure-function claims require the statutory disclaimer and notification to FDA within thirty days of first marketing.